Moxifloxacin (oral): Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Moxifloxacin}} | {{Moxifloxacin}} | ||
{{CMG}};{{AE}}{{AK}} | {{CMG}};{{AE}}{{AK}} | ||
'''''For patient information, click <u>[[Moxiloxacin(patient information)|here]]'''''</u> | '''''For patient information, click <u>[[Moxiloxacin(patient information)|here]]'''''</u> | ||
Revision as of 08:42, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
For patient information, click here
Overview
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox® (in some countries also Avalox®) for oral treatment. Each tablet contains 400 mg. In most countries the drug is also available in parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the name Vigamox® for the treatment of conjunctivitis.
Category
Fluoroquinolone, fourth generation.
US Brand Names
AVELOX®, MOXEZA®, VIGAMOX®.
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21277slr018,21085slr023_avelox_lbl.pdf